沃森生物：与合作方共同合作联合研发的呼吸道合胞病毒mRNA疫苗已于2025年8月申报临床研究获得受理

Group 1 - The company Watson Bio is developing an mRNA vaccine for respiratory syncytial virus (RSV) in collaboration with partners [2] - The clinical research application for the RSV vaccine has been accepted as of August 2025 and is currently in the technical review stage [2]